Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patient impact.   Download Full Press Release Press inquiries should be adressed to: Claus Andersson, PhD General Partner    Indlægget Fund IV company Cardior Pharmaceuticals acquired by No ..read more

A Sunstone team update After 17 years as General Partner and co-founder of Sunstone Life Science Ventures and almost 40 years in the life science industry, our colleague Sten Verland will be taking on a part-time role as Venture Partner as of February 1. Sten will continue to manage his current portfolio and will stay on the boards of these companies, and we will fortunately still have Sten involved when sourcing and evaluating new investment opportunities. Sten has been a CEO, a business angel and a VC and has a unique perspective on our industry. We are very pleased that we can continue ..read more

Sunstone Life Science Ventures divests its holding in Arcoma AB Sunstone announces that one hundred percent of the holding in Arcoma AB have been sold in a structured block sale. Sunstone has been a major owner in Arcoma since 2010 and is proud of what the company has achieved in delivering world-class digital radiographic systems. The investment was placed in Sunstone Life Science Venture Funds II established in 2007. The fund is under liquidation and the divestment is a step in the process to return proceeds to the investors in the Fund and is in no way related to the current status or p ..read more

Sunstone Life Science Ventures joins EUR 57 Million Series A Investment in Kynexis to Advance Development of Novel Therapeutics for Cognitive Disorders Sunstone Life Science Ventures (Sunstone), a leading Nordic venture capital firm, is excited to announce its participation in a EUR 57 million Series A funding round for Kynexis B.V., a pioneering biotech company dedicated to advancing treatments for cognitive impairment associated with schizophrenia. Jacob Lange Moresco, Investment Director with Sunstone, will be joining Kynexis’ board of directors as part of this investment. Download Ful ..read more

Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developing a first-in-class regenerative treatment for type 1 diabetes Sunstone Life Science Ventures (Sunstone), a leading European venture capital firm focused on life science therapeutics, today announced that Sunstone’s Fund IV has invested in the Series A financing round of DiogenX now increased to €33.5 million ($33.8M).  Download Full Press Release Press inquiries should be adressed to: Claus Andersson, PhD General Partner    Indlægget Sunstone Life Science Ventures Fund IV invests ..read more

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its novel GBS vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide. It is normally associated with infection in pregnant women and new-born babies; however, invasive GBS disease in adults has been increasing over the ..read more

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor’s Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from can ..read more

Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of the patient enrollment in the company’s pivotal phase 3 clinical study SPARKLE with the lead candidate drug Orviglance®.  Download Full Press Release Press inquiries should be adressed to: Søren Lemonius Managing General Partner     Indlægget Ascelia Pharma meets major milestone with ..read more

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it’s important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing, and we’re often consulted on the topic of PIPEs in Scandinavia.Recent data shows that pre-commercial life science companies currently have 460 MEUR at their disposal but burn rates have increased and runway is at its lowest point in 3 years. Among the 73 companies classified as “Biotech Industry” on the stock exchanges in Cope ..read more

A ..read more